We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Zeiss Light and Electron Microscopy Combined in New Business Group

By LabMedica International staff writers
Posted on 28 Nov 2011
The Carl Zeiss Group (Gottingen, Germany) has launched a new microscopy business group that combines microimaging and nanotechnology systems. More...
In the future, the company will be the world's only supplier to offer one-stop, innovative systems, and solutions for light and electron microscopy.

Customers are increasingly using both systems and want integrated software and workflow solutions. The combination of Carl Zeiss MicroImaging and Nanotechnology Systems into one business group fully reflects this trend.

"By fusing the two worlds of microscopy, we are opening up totally new perspectives to our customers in science and industry," says Dr. Ulrich Simon, head of Carl Zeiss Microscopy. "Carl Zeiss has been a pioneer in this field for more than 160 years. Carl Zeiss and Ernst Abbe together invented scientific microscopy more than 160 years ago. Since then, the company has constantly played a crucial role in shaping the progress of this technology. We are now opening an exciting new chapter in this success story."

The potential offered by combining light and electron microscopy is illustrated by Prof. Jeff Lichtman of Harvard University (Cambridge, MA, USA), who is pioneering brain mapping with light and electron microscopy by generating three-dimensional maps of the brain.

Competition is increasing all over the world: microscopy is a fast-growing market because it is increasingly developing into a basic technology that is now firmly established in many different fields. It is a market that is characterized by big providers and small specialists for specific technologies. The new Carl Zeiss Microscopy business group combines two strengths: it has the right size to carry clout and offers technological expertise covering the entire microscopy process.

Related Links:
Carl Zeiss Group
Harvard University



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Immunofluorescence Analyzer
IFA System
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.